- Policy
- First reimbursement of Yuhan Pregabalin 75mg CR
- by Lee, Tak-Sun May 8, 2023 05:41am
- Yuhan Corporation became the first company in Korea to list Pregabalin 75mg SR tablets for benefit. This drug is used as an initial dose for patients with moderate renal impairment. According to the industry on the 6th, Yuhan Pregabalin SR 75mg has been listed at 513 won per tab since May. Various doses of Pregabalin, such as 25 mg, 50 mg, 15
- Policy
- The expansion of MPOX vaccination
- by Lee, Jeong-Hwan May 3, 2023 05:38am
- 17 million adult males aged 20 to 64, 170,000, about 1%, the high-risk group estimated As the number of MPOX cumulative confirmed cases in Korea increased to 49, concerns about community infection grew, and domestic quarantine authorities decided to expand the target of third-generation MPOX vaccine to 'high-risk subjects of infection', draw
- Policy
- Pemazyre received domestic product approval
- by Lee, Hye-Kyung May 2, 2023 03:40pm
- Handok's locally advanced or metastatic cholangiocarcinoma treatment Pemazyre received domestic product approval on the 25th. The Ministry of Food and Drug Safety (Minister Oh Yoo-kyung) announced that it had approved three doses (4.5mg, 9mg, 13.5mg) of Pemazyre, an orphan drug. Pemazyre is an oral FGFR inhibitor that inhibits the proliferati
- Policy
- Dual punishment for CSO rebate excluded from review
- by Lee, Jeong-Hwan Apr 28, 2023 05:49am
- An amendment to the Medical Service Act that applies a dual punishment system when doctors receive rebates paid by pharmaceutical contract sales organizations (CSOs) and an amendment to the Pharmaceutical Affairs Act to prohibit potential hospital/pharmacy owners and brokers from exchanging illegal hospital subsidies in exchange for prescr
- Policy
- JW Pharma Hemlibra will be reimbursed starting in May
- by Lee, Tak-Sun Apr 25, 2023 05:56am
- JW Pharma's Hemlibra will also be covered for patients with severe non-antibody hemophilia A from May. Previously, this drug was covered only for hemophilia A patients with antibodies. This increase in coverage is expected to greatly contribute to the quality of life of patients with severe non-antibody hemophilia A, especially pediatric p
- Policy
- Original Concor voluntarily reduced the price
- by Lee, Tak-Sun Apr 25, 2023 05:56am
- Concor (Bisoprolol fumarate), the original β-blocker antihypertensive drug, voluntarily lowered its drug price, gaining recognition and price competitiveness. Many generic drugs are more expensive than original drugs, so marketing activities are expected to be difficult. According to the industry on the 24th, the price of Concor 5mg will go
- Policy
- Price of Eliquis reduced by 3.5%... Kanarb by 1.7% each
- by Kim, Jung-Ju Apr 24, 2023 05:52am
- Merck's Mavenclad tab. (cladribine), which is used to treat relapsing-remitting multiple sclerosis, has become subject to price cuts under the price-volume agreement and will be sold at a 6.9% lower price starting next month. The price of Boryung’s flagship hypertension drug, Kanarb (fimasartan potassium trihydrate), will be reduced by 1.7%
- Policy
- The price of Envlo is 611 won & Qtern is 833 won per tab
- by Lee, Tak-Sun Apr 23, 2023 09:42pm
- Leading diabetes treatments such as Daewoong Pharmaceutical's new SGLT2i diabetes drug Envlo and AstroGeneca's SGLT2i+DPP4i complex Qtern will be poured out at once in May. In line with the expansion of the Forxiga patent expiration and diabetes drug combined salary standards this month, the application of new product benefits was concentrate
- Policy
- CPAC 'Reducing PMS cases for Zerbaxa deemed valid'
- by Lee, Hye-Kyung Apr 21, 2023 05:56am
- Experts in Korea have agreed that it is valid for MSD Korea to change its post-marketing surveillance plan for ‘Zerbaxa inj (ceftolozane/tazobactam),’ which is used to treat severe multidrug-resistant Pseudomonas aeruginosa infections, in consideration of its usefulness and usage. The biggest reason was due to the company’s difficult
- Policy
- SGLT2 Domestic new drug/combined drug market
- by Lee, Tak-Sun Apr 20, 2023 05:58am
- Forxiga, Jardiance, Suglat, and Steglatro have been market-leading SGLT-2 inhibitors as weight-loss diabetes drugs. Domestic pharmaceutical companies are also fighting back. Domestic pharmaceutical companies that have relaxed with Generic for Forxiga are anticipating a full-fledged offensive from next month with Daewoong Pharmaceutical's new
